2083 POSTER Adjuvant delivery of a dose-dense, sequential FEC-docetaxel regimen to patients with high-risk breast cancer is feasible – results of a randomized, open-label Phase II study

✍ Scribed by H. Wildiers; L. Dirix; P. Neven; A. Prové; P. Clement; F. Amant; R. Paridaens

• Book ID: 118625687
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 61 KB
• Volume: 5
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(07)70845-5